← All Novo Nordisk A S filings

Novo Nordisk A S 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NYSE
NVO
Novo Nordisk A S
20-F: Novo Nordisk Navigates Transformation Amidst GLP-1 Market Shifts
Novo Nordisk reports 6.4% sales growth in 2025, driven by obesity and diabetes care, but anticipates a sales decline in 2026 due to increased competition and pricing pressures.
NYSE
NVO
Novo Nordisk A S
20-F: Novo Nordisk A/S Releases 2024 Annual Results, Highlights Growth in Diabetes and Obesity Care
Novo Nordisk A/S reports strong 2024 results driven by its Diabetes and Obesity care segment, while also outlining its commitment to sustainability and innovation.
NYSE
NVO
Novo Nordisk A S
20-F: Novo Nordisk Reports Strong 2023 Results, Navigates Supply Constraints and Expands Pipeline
Novo Nordisk's 2023 annual report highlights significant sales growth driven by diabetes and obesity care, while addressing supply challenges and expanding its pipeline through strategic acquisitions and R&D investments.